| scholarly article | Q13442814 |
| P356 | DOI | 10.1507/ENDOCRJ.50.61 |
| P953 | full work available at URL | https://www.jstage.jst.go.jp/article/endocrj/50/1/50_1_61/_pdf |
| http://www.jstage.jst.go.jp/article/endocrj/50/1/50_1_61/_pdf | ||
| P698 | PubMed publication ID | 12733710 |
| P2093 | author name string | Hiroshi Yamaguchi | |
| Takeo Kato | |||
| Makoto Daimon | |||
| Kazuhiko Sugiyama | |||
| Hiroshi Ohnuma | |||
| Masahiko Igarashi | |||
| Tamotsu Saitoh | |||
| Toshihide Oizumi | |||
| Wataru Kameda | |||
| Akihiko Hirata | |||
| P2860 | cites work | Renal catabolism of advanced glycation end products: the fate of pentosidine | Q28261351 |
| Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline | Q28319359 | ||
| The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation. | Q30307748 | ||
| Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications | Q34049428 | ||
| Advanced glycation end-products: a review | Q34196489 | ||
| Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats | Q35931294 | ||
| Protein-bound acrolein: potential markers for oxidative stress | Q36058528 | ||
| Determination of urinary pyrraline by solid-phase extraction and high performance liquid chromatography | Q43710869 | ||
| Advanced glycosylation end products in patients with diabetic nephropathy | Q44031994 | ||
| Glycaemic control and in vivo non-oxidative Maillard reaction: urinary excretion of pyrraline in diabetes patients. | Q50927098 | ||
| Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. | Q54342368 | ||
| Determination of urinary and serum pentosidine and its application to elder patients. | Q54796967 | ||
| Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects | Q67737660 | ||
| Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts | Q67993919 | ||
| Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD | Q72735556 | ||
| The Maillard protein cross-link pentosidine in urine from diabetic patients | Q72898755 | ||
| Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis | Q73543419 | ||
| Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy | Q77762044 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endocrinology | Q162606 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 61-67 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Endocrine Journal | Q5376304 |
| P1476 | title | Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes | |
| Increased Urinary Levels of Pentosidine, Pyrraline and Acrolein Adduct in Type 2 Diabetes | |||
| P478 | volume | 50 |
| Q28647896 | A possible role of acrolein in diabetic retinopathy: involvement of a VEGF/TGFβ signaling pathway of the retinal pigment epithelium in hyperglycemia |
| Q28711096 | Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress |
| Q36365757 | Acrolein generation stimulates hypercontraction in isolated human blood vessels |
| Q42123409 | Acrolein induces vasodilatation of rodent mesenteric bed via an EDHF-dependent mechanism |
| Q39908847 | Acrolein metabolites, diabetes and insulin resistance. |
| Q54218753 | Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. |
| Q37627117 | Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C. |
| Q58088593 | Adverse effects of acrolein, a ubiquitous environmental toxicant, on muscle regeneration and mass |
| Q38290083 | Biomarkers in diabetic nephropathy: Present and future |
| Q73485916 | Current literature in diabetes |
| Q46470193 | Evaluation of N (epsilon)-(3-formyl-3,4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy |
| Q43502757 | Functional analysis of the AKR4C subfamily of Arabidopsis thaliana: model structures, substrate specificity, acrolein toxicity, and responses to light and [CO(2)]. |
| Q39718789 | Localization of Acrolein-Lysine Adduct in Fibrovascular Tissues of Proliferative Diabetic Retinopathy. |
| Q27686784 | Mechanisms of hemorrhagic cystitis. |
| Q37291226 | New insights in the pathogenesis of multiple sclerosis--role of acrolein in neuronal and myelin damage |
| Q34113288 | Role of endoplasmic reticulum stress in acrolein-induced endothelial activation |
| Q47233622 | Skeletal muscle insulin resistance is induced by 4-hydroxy-2-hexenal, a by-product of n-3 fatty acid peroxidation. |
| Q28384340 | Sulforaphane protects against acrolein-induced oxidative stress and inflammatory responses: modulation of Nrf-2 and COX-2 expression |
| Q36452887 | The effects of acrolein on the thioredoxin system: implications for redox-sensitive signaling |
| Q37707267 | Urinary biomarkers involved in type 2 diabetes: a review. |
| Q36178739 | Urinary biomarkers of oxidative status |
Search more.